Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study

Background. Hepatorenal syndrome (HRS) is a severe complication of cirrhosis and is associated with high mortality. Ornipressin and terlipressin are effective in treatment of HRS, but are not available in the USA. The efficacy of vasopressin (AVP) and octreotide (OCT) infusions, commonly utilized in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation dialysis, transplantation, 2005-09, Vol.20 (9), p.1813-1820
Hauptverfasser:	Kiser, Tyree H., Fish, Douglas N., Obritsch, Marilee D., Jung, Rose, MacLaren, Robert, Parikh, Chirag R.
Format:	Artikel
Sprache:	eng
Schlagworte:	acute renal failure Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibiotics. Antiinfectious agents. Antiparasitic agents Antidiuretic Agents - therapeutic use Antiviral agents Arginine Vasopressin - therapeutic use Biological and medical sciences cirrhosis Cohort Studies dopamine Emergency and intensive care: renal failure. Dialysis management Female Glomerulonephritis Hepatorenal Syndrome - drug therapy Humans Intensive care medicine Male Medical sciences Middle Aged mortality Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Octreotide - therapeutic use Pharmacology. Drug treatments recovery response Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!